Practical steps in the diagnosis and management of gout

BioDrugs

Volumn 14, Issue 2, 2000, Pages 99-107

  Jelley, Martina J ^a   Wortmann, Robert ^a  

^a UNIVERSITY OF OKLAHOMA HEALTH SCIENCES CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALLOPURINOL; AZATHIOPRINE; BENZBROMARONE; COLCHICINE; CORTICOSTEROID; CORTICOTROPIN; FLURBIPROFEN; IBUPROFEN; INDOMETACIN; KETOPROFEN; MERCAPTOPURINE; NAPROXEN; NONSTEROID ANTIINFLAMMATORY AGENT; PIROXICAM; PREDNISOLONE; PROBENECID; SULFINPYRAZONE; THIAZIDE DIURETIC AGENT; TRIAMCINOLONE; URATE; URICOSURIC AGENT;

ABDOMINAL PAIN; ALOPECIA; ANTIINFLAMMATORY ACTIVITY; BONE MARROW SUPPRESSION; BONE MARROW TOXICITY; CHRONIC ARTHRITIS; CLINICAL FEATURE; DIARRHEA; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG HALF LIFE; GASTROINTESTINAL DISEASE; GOUT; HEADACHE; HUMAN; HYPERSENSITIVITY; HYPERTENSION; HYPERURICEMIA; INTERSTITIAL NEPHRITIS; KIDNEY FAILURE; LIVER TOXICITY; MAINTENANCE THERAPY; METATARSOPHALANGEAL JOINT; MONARTHRITIS; NAUSEA; NEPHROLITHIASIS; NEUROPATHY; PATIENT EDUCATION; PRIORITY JOURNAL; REVIEW; STEVENS JOHNSON SYNDROME; TREATMENT CONTRAINDICATION; URTICARIA;

EID: 0033828580     PISSN: 11738804     EISSN: None     Source Type: Journal    
DOI: 10.2165/00063030-200014020-00004     Document Type: Review

References (32)

1. Hall AP, Berry PE, Dawber TR, et al. Epidemiology of gout and hyperuricemia - a long-term population study. AM J Med 1967:42: 27
2. Lawrence RC, Hochberg MC, Kelsey JL, et al. Estimates of the prevalence of selected arthritic and musculoskeletal diseases in the United States. J Rheumatol 1989; 16: 427-41
3. Campion EW, Glynn RJ, DeLabry LO. Asymptomatic hyperuricemia: risks and consequences in the Normative Aging Study. Am J Med 1987; 82: 421-6
4. Hench PS. The diagnosis of gout and gouty arthritis. J Lab Clin Med 1936:220:48
5. Wyngaarden JB, Kelley WN. Clinical description of classic gout. In: Gout and hyperuricemia. New York: Grune & Stratum, 1976: 214
6. Linton RR, Talbott JH. Surgical treatment of tophaceous gout. AnnSurg 1943; 117: 161-82
7. Wortmann RL. Gout and other disorders of purine metabolism. In: Fauci AS, editor. Harrison's principles oof internal medicine. 14th ed. New York: McGraw-Hill, 1998: 2158-66
8. Caspi D, Lubart E, Graff B, et al. The effect of mini-dose aspirin on renal function and uric acid handling in elderly patients. Arthritis Rheum 2000; 43: 103-8
9. Roberge CJ, Gaudry M, de Medicis R, et al. Crystal-induced neutrophil activation. IV. Specific inhibition of tyrosine phosphorylation by colchicine. J Clin Invest 1993; 92: 1722-9
10. Spilberg I, Mandell B, Mehta J, et al. Mechanism of action of colchicine in acute urate crystal-induced arthritis. J Clin Invest 1979:64: 775-80
11. Ahern MJ, Reid C, Gordon TP, et al. Does colchicine work? The results of the first controlled study in gout. Aust N Z J Med 1987; 17: 301-4
12. Wallace SL, Ertel NH. Colchicine: current problems. Bull Rheum Dis 1969; 20: 582-7
13. Wallace SI, Singer JZ. Review. Systemic toxicity associated with the intravenous administration of colchicine - guidelines for use. J Rheumatol 1988; 15: 495
14. Wallace SL, Singer JZ. Therapy in gout. Rheum Dis Clin North Am 1988; 15:441-57
15. Agudelo CA. Gout and hyperuricemia. Curr Opin Rheumatol 1989: 1:286-93
16. Groff CD, Franck WA. Raddatz DA. Systemic steroid therapy for acute gout: a clinical trial and review of the literature. Semin Arthritis Rheum 1990; 19: 329
17. Ike RW. Therapeutic injection of joints and soft tissue. In: Klippel JH, editor. Primer of rheumatic disease. 11th ed. Atlanta: Arthritis Foundation, 1997: 417-21
18. Axelrod D, Preston S. Comparison of parenteral adrenocorticotropic hormone with oral indomethacin in the treatment of acute gout. Arthritis Rheum 1988; 31: 803-5
19. Groff GD, Franck WA, Raddatz DA. Systemic steroid therapy for acute gout: a clinical trial and review of the literature. Semin Arthritis Rheum 1990; 19: 329-36
20. Yu T-F. The efficacy of colchicine prophylaxis in articular gout - a reappraisal after 20 years. Semin Arthritis Rheum 1982; 12:256-64
21. Pascual E, Castellano JA. Treatment with colchicine decreases white cell counts in synovial fluid of asymptomatic knees that contain monosodium urate crystals. J Rheumatol 1992; 19: 600-3
22. Kuncl RW, Duncan G, Watson D, et al. Colchicine myopathy and neuropathy. N Engl J Med 1987; 316: 1562
23. Wallace AL, Singer JZ. Therapy in acute gout. Rheum Dis Clin North Am 1988; 14:441-57
24. Emmerson BT. Drug therapy: the management of gout. N Engl JMed 1996; 334: 445-51
25. Thompson GR. Duff IF, Robinson WD, et al. Long term uricosuric therapy in gout. Arthritis Rheum 1962; 5: 384-96
26. Dayton PG, Perel JM. The metabolism of probenecid in man. Ann N Y Acad Sei 1971 ; 179: 399-402
27. Lecaillon JB. Souppart C, Schoeller J-P, et al. Sulfinpyrazone kinetics after intravenous and oral administration. Clin PharmacolTher 1979; 26: 611-7
28. Zürcher RM, Bock HA, Thiel G. Excellent uricosuric efficacy of benzbromarone in cyclosporin-A-treated renal transplant patients: a prospective study. Nephrol Dial Transplant 1994; 9(51:548-51
29. Sorenson LB, Levinson DJ. Clinical evaluation of benzbromarone: a new uricosuric drug. Arthritis Rheum 1976; 19: 126-40
30. Hände K, Reed E, Chabner B. Allopurinol kinetics. Clin Pharmacol Ther 1978; 23: 598-605
31. Hände KR, Noone RM, Stone WJ. Severe allopurinol toxicity: description and guidelines for prevention in patients with renal insufficiency. Am J Med 1984; 76: 47-56
32. Wortmann RL. Effective management of gout: an analogy. Am JMed 1998; 105:513-4